#2-86E. Dual Strike on Lupus: Ianalumab's Promise for Steroid-Free Remission (Ann Rheum Dis, 2025)

Achieving sustained remission in systemic lupus erythematosus (SLE) while minimizing corticosteroid toxicity remains a formidable clinical challenge. In this episode, we explore a pivotal Phase 2 randomised trial evaluating ianalumab, a novel monoclonal antibody that simultaneously depletes B cells and blocks BAFF receptor signaling. The study investigated whether this dual-mechanism approach, added to standard care, could improve outcomes in moderate-to-severe SLE. The core finding is remarkably promising: 44.1% of patients receiving ianalumab met the primary composite endpoint of SRI-4 response coupled with successful corticosteroid tapering, compared to only 9.1% in the placebo group. This indicates a potent ability to control disease activity while facilitating crucial steroid reduction. However, when critically appraising these results, listeners should note the study's limited sample size of 67 patients and its Phase 2 design, which mandates validation in larger Phase 3 trials before widespread adoption. Despite these limitations, this research is vital for clinicians as it highlights a potential breakthrough in steroid-sparing strategies, suggesting that dual-targeting of B cells could become a cornerstone of future lupus management.

Citation: AGMON-LEVIN, N., et al. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Ann Rheum Dis. 2025. DOI: 10.1016/j.ard.2025.11.015

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.